Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At this point it appears that is the case, but there maybe value in the shell as all of the debt will get discharged with the completion of the bankruptcy. We maybe looking at a few cents value for our shares if they bring this back off of the grey-sheets.
Company of interest Sanofi, who appears to have long ago converted their common shares of Kalobios into preferred shares, today released a 6-K regarding several of their mabs and clinical trials. Also included was a press release concerning the appointment of three new Independent Directors. I wonder if the new Independent Directors are being appointed to gain Nasdaq compliance in the US, ahead of the spin-off of their healthcare division.
https://www.sec.gov/Archives/edgar/data/1121404/000119312524047460/d702412d6k.htm
VIKING Therapeutics — The clinical-stage biotech soared more than 90% after fulfilling primary and secondary endpoints in its Phase 2 GLP-1 study. Viking said its Phase 2 Venture trial showed weight loss in patients receiving the VK2735 treatment.
I don’t know man, but to me it looks like Durrant took Lenz and left us with debt and a shell…Jay keeps talking about a share recall, I don’t see it, a share recall if possible would have happened before they decide to sell the assets.
IMO it would have made sense to do that before Ch11, cause the squeeze and bring value to the shares and raise capitol for the company. That idn’t happen….
We may get lucky with a bone tossed to common shares, but a squeeze and a share recall doesn’t sound like it would make sense at this point.
I think Durrant gave up trying to run HGEN. He has taken his work somewhere else and left us holding our bags.
Can somebody please update me where we stand with our shareholder positions? Are we dissolving/invalidating our shares such as transferring the ip to Taran or is Humanigen still going to remain active and viable? I stepped away from the board for a few because new accounts are appearing and seem to be spamming the board.
With Gracell having completed becoming a subsidiary of AstraZeneca, and deregistering their stock on Nasdaq, I'm going to replace them with Sanofi (SNY) as one of the stocks I watch for SEC filings.
Sanofi is showing several recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?CIK=0001121404&owner=exclude
I don't think you're giving full consideration to both Humanigen's and Taran's blank-slate foreign subsidiaries, and to how they may be used to capitalize on the use of the Excluded Assets recognized by the bankruptcy court judge. And that is totally understandable, and intended. I think that same lack of understanding is shared by certain of the unsecured creditors, who should appreciate management's ongoing effort which is, in part, on their behalf, in my opinion.
I don't see any real change, or impediments, to the accomplishment of management's goals. In fact, I see just the opposite, as management is free to proceed without the degree of financial constraints they have been under.
Humanigen management ran the company into the ground, didn't need to file bankruptcy except that prior management got the company for a credit bid, and netted that out with the Australian receivable.
Terrible managers of the business but brilliant in bankruptcy proceedings. Give the BOD props for that one.
Did we ever get played.
Great summaries of the filings, Biowa.
I will do that on the 2nd Million! :))
come on, at least make it for $2 or $3!
Any shorts who are desperate to cover I am giving you a Gift as I have 1 million shares up for sale at .40 cents per share.
The rest I will hold for much higher gains.
The judge in this case handles 10 cases per year. you think he has the time or resources to do full 'investigation' bankruptcy filing is procedure and lots of precedent cases.. no need to appeal. case closed.
there is less than 20 shareholders one shareholder owns 90% of the shares and is the controlling shareholder. I'm helping myself with this analysis of the situation and case. obviously the courts dont have the time or resources for such deep analysis of the chapter 11. With secure loans the creditors own the assets and equity and there is no auction. liquidating assets is chapter 7 when all assets are liquidated and any money left to repay any creditor. in this case there is no money or cash to pay any of the UNSECURED creditor 'fake claims' or unreasonable disputed claims, the defendent or debtor nor the court has the time to hear or prove whether those UNSECURED DISPUTED 'claims' or valid..in chapter 11 all creditor claims are DISCHARGED.
Well, another newly created account for the purpose of helping us poor HGEN holders. How nice you are. Oh, now I realize you are a trumper/magat.
The Judge could have just said , get out of my court and stop wasting the court time and cased closed to the creditor committee and debtor filing the chapter 11
you have fools who think they can sue if they lose in sport bet.
many types of creditors in priority
1. SECURE Loans. humanigen has none
2. secure loans. humanigen has none
3. Credit extensions from vendors ie rent, telco, parking fees, etc. debtor has an account and product or service 'delivered' or accrued or consumed by debtor
4. unknown disputed claimant or creditors = lawsuit, parking fines, tax payables etc.
The debtor humanigen even paid rent and salaries which it didn't have to.
the lowest is the unsecured and DISPUTED claims which was the 25 million and 7 million and 3 milllion of the shareholder lawsuit that was to pay .047/share to some group of shareholders who 'claim' they were 'defrauded' or 'harmed' and loss money on there gamble. and thought FDA would approve since the drug was in final state or phase 3 before FDA approval which could have meant sales of at least 1 billion and shares goes to $10/share which didn't but went to zero .15/share and now bankruptcy. now worthless The disgruntled shareholders who made the lawsuit are no longer shareholders and sold out. and still want payment for 'alledged; harm for their bad bet that they lost.
unsecured creditors or unsecured loans have lower priority than secure loans. Humanigen didn't have to auction off assets too since 75% of the creditors were UNSECURED loans and possibly fake creditor claims which are 'disputed' SECURE LOANS like bank loans are not disputable and humanigen has 'NO SECURE BONDS or SECURED line of credit.' they didn't even have to pay the bogus creditor claims but chose the easy way out of bogus creditor claims or bogus lawsuits and declare chapter 11 and bail
The creditor committee could have made a bid for the assets. yet the creditor committed didn't even bother trying to bid for the assets since the assets were 'worthless'
The court doesn't have the resources of staff to investigate some claim of 7,1 million from Chime medical which is based in China too. And chime didn't even bother objecting to the chapter or sales of assets. You think if someone who supposedly owes you $7 million you at least appear in court and file an objection.
The court didn't ask for proof or evidence that the creditor claims were genuine.
It says 'fake' creditor claims can result in $500,000 fine but there is no way to prove or enough resources to prove the creditor claims are fake unreasonable amounts like lawsuits, penalties, fines etc. It's like the 454 million dollar civil lawsuit that a Judge ordered Trump to pay. It's a bogus and unreasonable 'claim' on Trump estate for alledged harm it did to some lender for 'fraud' when' no harm' was inflicted on the lender. and complainant didn't suffer any harm, yet Judge gives some entity $454 million dollars in politically motivated persecution of Trump to prevent him from running for Presidency.
Humanigen has no SECURE LOANS.
All the creditor claims are unsecured creditor claims and 75% of the creditor claims is 'disputed'
Humanigen didn't even have to auction or sell any of it's assets unlike a chapter 11
SECURE CREDITORS in chapter can own the assets and own the equity since it was put up for COLLATERAL.
this was actually a chapter 7 in execution which humanigen the creditor was not obligated to sell or auction anything.
The fact is that the bankruptcy court judge did not convert the case from CH11 to CH7.
"Motions to convert to Chapter 7 for cause may be granted if the court examines the facts of the case and finds one or more of the following:
The debtor has no profitable core business around which to structure a reorganization.
The debtor cannot or will not formulate a reasonable reorganization plan.
The debtor’s financial picture indicates little or no ability to generate income and as such there is little reasonable likelihood of rehabilitation.
The debtor’s business is suffering continuing losses by remaining in operation, which may be shown by its negative cash flow during Chapter 11 and/or its inability to pay ordinary costs of business such as insurance, taxes and interest.
The debtor has failed to comply with the court’s filing and reporting requirements, thus showing that it has not exercised the due diligence expected of a Chapter 11 debtor.
The debtor is not using Chapter 11 for a legitimate reorganization effort or is otherwise not acting in good faith."
https://www.bankruptcypower.com/blog/when-can-a-court-convert-your-chapter-11-reorganization-to-a-chapter-7/
The judge found NONE of the above. Durrant, who knows more about our pathway than anyone, except Dale, is investing millions more into lenzilumab and our product pipeline. I think the AstraZeneca/Gracell/and Grey Wolf merger sub transactions, may represent a structural template of what we may see. Regardless, we are Humanigen shareholders, and we will be the financial beneficiaries of a recall of the loaned HGEN shares. As I showed in the historical record of the first recall of our loaned shares, business fundamentals are meaningless, if brokerages are forced into buying-in their customers' short position by a recall of the loaned shares.
With one major exception, I think management planned for this potential outcome from the start, and designed their share structure to capitalize on this eventuality, as they had to do to protect the company and their shareholders. The unplanned exception was the covid pandemic, which raised the risk/reward ratio exponentially, and we are about to experience the "reward" part of that ratio.
When is the post chapter 11 report?
showing the companies assets and liabilities?
after chapter 11 all the creditor claims normally get discharged.. the company no longer have any assets. to repay any creditor claims.
The Judge h as a lot of power to force the company to disclose the owners of the company or any benefectors of the owners of the company. you have 4 entities owned by same person entity owning 90% of the company or one person or one entity has total control of the company matters or access to the bank. or payments. over $400,000 in legal fees was paid in january 2024. 160,000 and 200,000 wire transfers in just one month for legal services.
there is no shareholder meeting too. it's basically a private company now.
Right now, the company has less than 30 shareholders and one shareholder owns 90% of the outstanding shares. it's not making anything public because SEC rules.
After chapter 11
All the creditor claims are are discharged including the lawsuit of $3 million.
All lawsuits are discharged after chapter 11. so why even have the march 12 hearing?
after chapter 11, there is no CEO , no board or directors, just shell company. who will administer any corporate matters like payments, listing fees, and corporate bank accounts or have control of the company's bank accounts.?
In traditional auction or real auction, starting bid is 0.
That is why this stalking bidder thing is rigged. or nonsense it's not an auction. when only one bidder
if the stalking bidder was starting bid was $10,000, and assets was valued assets valued at $15 million then you get more bidders rushing to bid. or registered. the court or didn't receive any 'qualified' bid as there was bid. nobody want to pay more that it's worth.
The stalking bidder got all of humanigen assets. and can sell the assets for 2 million. because that is what it is 'worth' the $2 million was the minimum bid if the staling bid was $100,000 and value of assets was appraised at $15 million. you get bidders more bidders. or at least 100 bidders why bid more than it's worth. it's like the car is worth $99,000 at an auction and house bid is $100,000. and anyone bidding higher has to pay the house $1000
The auction was cancelled as no 'qaulified' bidder was received as they 'claimed'. The court has to approve the bidder.
It’s over Jay, if Lenz was worth anything it wouldn’t have been given to Durrant for 2 million. There would have been an interest in bidding….there wasn’t anything.
He gets Lenz we get a shell that may be worth a few Pennie’s down the road.
Durrant remains in control of the product pipeline. I don't think the Taran CEO is going to do anything that the HGEN CEO doesn't want to do, that is, assuming the two companies remain distinct entities, which I doubt they will.
Humanigen doesn't own Lenz anymore. Not sure if they still own ifabotuzumab
Sanofi hasn't garnered much attention here. I did, however, previously note that they appear to have been one of the beneficiaries of Humanigen's Original Issuance of Shares (OIS). As I recall, I think their stake was for less than 5% of our shares, and did not require the filing of a beneficial ownership statement. I mention them again because of their announced intention to spin-off their healthcare division, resulting in a separate listing later this year. So, it's a timing consideration regarding an entity that may have a long-standing knowledge of our objectives and capabilities that prompts me to mention them again.
But, something else that's been mentioned lately is a privately held pharmaceutical company, such as we were engaged with at one time with the objective of establishing a business combination. My thought at the time we announced that objective was that PCI Pharma may have been our prospective partner, and that may still be true. But another candidate for a business combination has developed. I'm referring to AstraZeneca. I think lenz would be compatible with their Covishield adenovirus vaccine. Another consideration would be that Gracell has now become a subsidiary of AstraZeneca.
"SAN DIEGO and SUZHOU, China and SHANGHAI, China, February 22, 2024 -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent." The mechanics of this transaction fascinate me, too, if Humanigen uses one of their foreign subsidiaries, or Taran uses one of their subsidiaries, as a merger sub in bringing AZ and HGEN together.
https://www.sec.gov/Archives/edgar/data/1826492/000110465924026350/tm246846d1_ex99-1.htm
I continue to think, however, that Novavax offers the most synergy with Humanigen. I did not think that Novavax would survive without using lenz to enhance their prototype Covid vaccine. And they may not. But recent news is developing on two fronts that could have a profound impact on Humanigen's lenz for covid, AstraZeneca, Novavax, and Humanigen could all see dramatic increases in demand for their non-mRNA covid products if, for example, the Department of Defense, through our BARDA or CRADA agreements, has asked Humanigen for a stockpile of lenz (even if the House is also focused on Russia's possible deployment of nuclear missiles in outer space).
I have long said that I think lenz has the potential to stop, or to have stopped, millions of preventable covid deaths. Tough to do, if the Johns Hopkins covid data was correct, when they stopped collecting data in March of 2023, when they were reporting 6.9M covid deaths.
https://coronavirus.jhu.edu/map.html
But I am now seeing several sources, including Bret Weinstein and Steve Kirsch, using VAERS data and time modulated cohort analyses, report that the actual covid death toll in vaccinated patients has been in the range of 13M-17M people. Of course, factcheck.org disputes that.
🚨 Estimated 13 - 17 million deaths from the COVID vaccine, "It's over 13 million people easily."
— Tucker Carlson Network (@TCNetwork) February 23, 2024
Watch @TuckerCarlson and @stkirsch discuss the estimated death toll from the COVID vaccine: pic.twitter.com/c1u7lwPfvn
"Still in progress are developments regarding Baudax/Tera-Immune, and Humanigen/Taran."
Sometimes, the people who got you where you are, are not the people who will take you where you're going. But sometimes, they are the same. "ND" announced three days ago that they are looking for acquisitions.
I wish I had some information about the resolution of Dale's Appeal. Common sense tells me that he prevailed, since it appears that things appear to be progressing with Taran. But that Appeal could have significance in regards to "ND" developments. "Timing" is the only reason I hint at this, along with history.
"I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax." Progress report.
Now, Form 25-NSE filings have been made for three of the above companies, to remove their stock from listing on the Nasdaq.
We know that news has now been reported for Novavax and Gracell.
Novavax:
"Novavax settles dispute with international vaccine group Gavi
By Michael Erman
February 22, 20249:43 AM CST
Shares of the company rose 23.2% to $4.91 on Thursday.
Its stock has dropped nearly 60% since the company last year raised doubts about its ability to remain in business. Nearly half of Novavax's free float shares were in short position, as of Jan. 31."
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-settles-dispute-with-international-vaccine-group-gavi-2024-02-22/
Noteworthy are the recent beneficial ownership filings.
https://www.sec.gov/cgi-bin/browse-edgar?company=novavax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm
Gracell:
"SAN DIEGO and SUZHOU, China and SHANGHAI, China, February 22, 2024 -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent."
https://www.sec.gov/Archives/edgar/data/1826492/000110465924026350/tm246846d1_ex99-1.htm
And again, we see a number of recently filed beneficial ownership statements for Gracell.
https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I think the efficacy of both Gracell's CAR-T, and the Novavax prototype vaccine, may prove to have been greatly enhanced by using lenzilumab in those applications. We haven't seen evidence of that yet. However, we certainly saw game-changing enhancement of CMML treatment using lenz in the PREACH-M study.
"MedicalResearch.com: What are the next steps in this study?
Response: The PREACH-M trial is a phase 2/3 trial. We plan to unveil new data showing comprehensive clinical responses according to established criteria, somatic mutation frequencies and bone marrow plasma inflammatory cytokine levels at international meetings later this year.
Humanigen and SAHMRI are assessing regulatory pathways that may enable early results to support a regulatory submission and potential provisional registration or approval by the Therapeutic Goods Administration in Australia. We are also considering opening up PREACH-M, or a similar study in other countries such as the UK and the US, subject to resourcing and Humanigen’s corporate strategy."
https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/#:~:text=The%20preliminary%20results%20from%20the,cells%20with%20RAS%2Dpathway%20mutations.
Still in progress are developments regarding Baudax/Tera-Immune, and Humanigen/Taran.
: a persistent false psychotic belief regarding the self or persons or objects outside the self that is maintained despite indisputable evidence to the contrary
You shouldn’t be!
Delusion
noun
de·?lu·?sion di-'lü-zh?n de-
Synonyms of delusion
1
a
: something that is falsely or delusively believed or propagated
under the delusion that they will finish on schedule
delusions of grandeur
b
psychology : a persistent false psychotic belief regarding the self or persons or objects outside the self that is maintained despite indisputable evidence to the contrary
the delusion that someone was out to hurt him
also : the abnormal state marked by such beliefs
2
: the act of tricking or deceiving someone : the state of being deluded
… accused the Bohemian of having practised the most abominable arts of delusion among the younger brethren.
—Walter Scott
Is Durrant getting an even bigger bang for his drug development bucks? I like the fact that Dale sold his Baudax shares, but that Intracoastal bought shares in the same time period. Will this present an opportunity for us regarding Tera-Immune?
Much more importantly, I see where Novavax announced today that they have entered into a Settlement Agreement with Gavi, regarding an Advanced Purchase Agreement.
https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm
https://www.cnbc.com/2024/02/22/novavax-to-settle-gavi-arbitration-over-canceled-covid-shot-purchase.html
The event that I am most looking forward to is the recall of our loaned shares, which may give me a brief moment to sell shares into a short squeeze.
But, the potential partnership that I am most looking forward to would be a stock-for-stock transaction with Novavax in a merger or business combination. I think that could lead to sustained annual revenue of over $67 per share, giving us a Market Cap in the $8B range.
The Gavi settlement greatly improves the outlook for Novavax to survive, and I hope it will prove another of the requirements for Humanigen to proceed with this venture (the first requirement was to significantly reduce R&D expense, which they have done). With the current institutional interest in Novavax, I am very excited about a possible pending announcement about a partnership with us.
It might be worth watching this development as it may relate to us. Too early to tell right now.
"Sanofi's consumer healthcare division draws private equity interest for spin-off. JPMorgan values it at $20B. Separate listing possible in Q4 2024. Other firms eyeing the unit."
Everything that Patheon wrote is 100% accurate.
Doesn't matter when the account was created or the motivation, all info was from the filing documents.
The only asset HGEN may still have are the NOL's.
I have not yet seen that determination.
Wow, Sorry for all your bitterness. You created an account today just to spew all this shot?
Followers
|
327
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
43253
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |